Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug — RE-THINc ESRD  

End Stage Renal Disease Requiring Hemodialysis Clinical Trial

Official title: Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of BAY 2976217

Status Completed

Clinical Trial Summary

Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow that causes heart attacks, strokes, and other life-threatening conditions. BAY2976217 is under clinical development for prevention of thrombosis. The goal of the study is to learn more about the safety of BAY2976217, how it is tolerated and the way the body absorbs, distributes and gets rid of the study dug given as multiple doses in participants with renal impairment who require hemodialysis.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• End Stage Renal Disease Requiring Hemodialysis
• Kidney Diseases
• Kidney Failure, Chronic

• NCT number: NCT04534114
• Study type: Interventional
• Source: Bayer
• Status: Completed
• Phase: Phase 2
• Start date: September 4, 2020
• Completion date: May 12, 2022